Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumacaftor/ivacaftor for exercise tolerance in cystic fibrosis with F508del homozygosity
2016-000066-34Phase 4Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in cystic fibrosis (CF) comparing Lumacaftor/ivacaftor with Placebo (2 arms). Primary endpoint: Percentage change from baseline in VO2max during cardiopulmonary exercise testing. Started Jul 2017; status: completed.
02
Drugs
lumacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2016-000066-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000066-34.